Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A403UF | ISIN: SE0022049920 | Ticker-Symbol: LS60
Frankfurt
15.05.25 | 09:15
0,233 Euro
+1,53 % +0,004
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CLINICAL LASERTHERMIA SYSTEMS AB Chart 1 Jahr
5-Tage-Chart
CLINICAL LASERTHERMIA SYSTEMS AB 5-Tage-Chart

Aktuelle News zur CLINICAL LASERTHERMIA SYSTEMS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
CLINICAL LASERTHERMIA SYSTEMS Aktie jetzt für 0€ handeln
28.04.ClearPoint Neuro, Inc.: ClearPoint Neuro, Together with its Partner Clinical Laserthermia Systems, Announces FDA Submission to Expand the Labeling of ClearPoint Prism to Include 1.5 T MRI67SOLANA BEACH, CA / ACCESS Newswire / April 28, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the...
► Artikel lesen
28.04.Clinical Laserthermia Systems, together with its partner ClearPoint Neuro, announces FDA submission to expand the labeling of ClearPoint Prism® to include 1.5 T MRI guidance3
15.04.Clinical Laserthermia Systems AB: Updated clinical guidelines provide clear recommendations on the use of Laser Interstitial Thermal Therapy (LITT) in patients with metastatic brain tumors and radiation necrosis64Clinical Laserthermia Systems AB (publ) ("CLS or the "Company") today announces that updated clinical guidelines with recommendations supporting the use of Laser Interstitial Thermal Therapy (LITT)...
► Artikel lesen
08.04.Clinical Laserthermia Systems AB: Proposed U.S. tariffs expected to have minimal impact on CLS business82Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or "the Company") clarifies that the proposed U.S. tariffs are expected to have minimal impact on its total business, including operations...
► Artikel lesen
27.02.Clinical Laserthermia Systems AB raises up to SEK 37m through a directed issue for accelerated commercialization and expansion1
24.02.Clinical Laserthermia Systems steigert Umsatz trotz Verlusten1
21.02.Clinical Laserthermia Systems AB: Clinical Laserthermia Systems AB publishes Year-end report January - December 2024141Summary of the year-end report (relates to the Group)Full year (01/01/2024-12/31/2024) Net sales totaled SEK 18,783,000 (SEK 8,273,000). Operating profit/loss totaled SEK -54,254,000 (SEK -65,933...
► Artikel lesen
07.02.Clinical Laserthermia Systems AB: CLS co-founder and former CEO Lars-Erik Eriksson leaves the board of directors at his own request1.055Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that Lars-Erik Eriksson, co-founder, long-time board member and former CEO, is leaving the board of directors...
► Artikel lesen
30.01.Clinical Laserthermia Systems AB: Data from the clinical trial using MRI-guided FLA with TRANBERG® Thermal Therapy System in patients with prostate cancer at Radboud University Medical Center (Nijmegen, NL) is now published1
14.01.Clinical Laserthermia Systems AB: CLS Recaps 2024 and Provides Outlook for 2025-26484Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that, in its recap of 2024, in the first nine months of 2024 compared to the same period 2023, CLS saw...
► Artikel lesen
09.12.24Clinical Laserthermia Systems AB: The Nomination Committee of Clinical Laserthermia Systems AB has been appointed in accordance with the guidelines for the Nomination Committee adopted at the Annual General Meeting on June 28, 2024.2
23.10.24Clinical Laserthermia Systems AB: CLS focus entirely on its successful neurosurgery business positioning the company for sustainable high-margin growth with a more streamlined operation183Lund, Sweden - Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces it will focus entirely on its successful neurosurgery business to drive sustainable high-margin growth...
► Artikel lesen
19.07.24Nasdaq Stockholm AB: New equity rights for trading, Clinical Laserthermia Systems AB TO 7 B431At the request of Clinical Laserthermia Systems AB, Clinical Laserthermia Systems AB equity rights will be traded on First North Growth Market as from July 22, 2024. Security name: Clinical Laserthermia...
► Artikel lesen
11.07.24Nasdaq Stockholm AB: New last trading day for paid subscription units (BTU) of Clinical Laserthermia Systems AB (Record Id 269640)370At the request of Clinical Laserthermia Systems AB, the last trading day in Clinical Laserthermia Systems AB's paid subscription units will be changed from 2024-07-12 to 2024-07-16. Instrument:...
► Artikel lesen
11.06.24Nasdaq Stockholm AB: Listing of unit rights and paid subscription units of Clinical Laserthermia Systems AB (Record Id 265418)581With effect from June 12, 2024, the unit rights in Clinical Laserthermia Systems AB will be traded on First North Growth Market. Trading will continue up until and including June 20, 2024. Instrument:...
► Artikel lesen
07.06.24XFRA CAPITAL ADJUSTMENT INFORMATION - 07.06.20241.570Das Instrument FKG US12776P5070 CAPRICORN E.LS-,034265734 EQUITY wird cum Kapitalmassnahme gehandelt am 07.06.2024 und ex Kapitalmassnahme am 10.06.2024 The instrument FKG US12776P5070 CAPRICORN E.LS-...
► Artikel lesen
29.05.24Clinical Laserthermia Systems AB: CLS publishes interim report January - March 2024239CLS publishes interim report January - March 2024Summary of the interim report (relates to the Group)Three months (01/01/2024-03/31/2024) Net sales totaled SEK 3,140,000 (SEK 587,000). Profit/loss...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1